NovAccess Global (OTCMKTS:XSNX – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Earnings and Valuation
This table compares NovAccess Global and Protagonist Therapeutics’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
NovAccess Global | N/A | N/A | -$4.72 million | ($0.10) | -0.05 |
Protagonist Therapeutics | $60.00 million | 24.83 | -$78.96 million | ($1.49) | -17.15 |
NovAccess Global has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than NovAccess Global, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Insider and Institutional Ownership
98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.4% of NovAccess Global shares are owned by company insiders. Comparatively, 5.0% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares NovAccess Global and Protagonist Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NovAccess Global | N/A | N/A | -877.60% |
Protagonist Therapeutics | N/A | -27.49% | -25.30% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for NovAccess Global and Protagonist Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NovAccess Global | 0 | 0 | 0 | 0 | N/A |
Protagonist Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Protagonist Therapeutics has a consensus target price of $36.00, indicating a potential upside of 40.85%. Given Protagonist Therapeutics’ higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than NovAccess Global.
Summary
Protagonist Therapeutics beats NovAccess Global on 7 of the 10 factors compared between the two stocks.
About NovAccess Global
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for NovAccess Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovAccess Global and related companies with MarketBeat.com's FREE daily email newsletter.